Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial

Blood (2023) 142 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2023-180010

Published: 2023

Journal Articles

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Hari S. Raman, Shai Shimony, Yannis K. Valtis, Yael Flamand, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna S. Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin

Blood (2023) 142 (Supplement 1): 1456.

https://doi.org/10.1182/blood-2023-178353

Published: 2023

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults

Marlise R. Luskin, Mark Alan Murakami, Julia Keating, Eric S. Winer, Jacqueline S. Garcia, Maximilian Stahl, Martha Wadleigh, Yael Flamand, Donna S. Neuberg, Ilene Galinsky, Rebecca Leonard, Ella Hagopian, Chase M Weizer, Carlin McLanahan, Richard M Stone, Eunice S. Wang, Wendy Stock, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 965.

https://doi.org/10.1182/blood-2023-174246

Published: 2023

Journal Articles

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Eric S. Winer, Jacqueline S. Garcia, Richard M Stone, Martha Wadleigh, Marlise R. Luskin, Maximilian Stahl, Evan C. Chen, Rebecca Leonard, Alexis Noyes, Ilene Galinsky, Rashmi Deshpande, Pascal Borderies, Vincent O'Neill, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2023-186598

Published: 2023

Journal Articles

A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults

Marlise R. Luskin, Shai Shimony, Julia Keating, Yael Flamand, Jacqueline S. Garcia, Rebecca Leonard, Thomas Reardon, Taylor Robertson, Chase M Weizer, Ilene Galinsky, Donna S. Neuberg, Richard M Stone, Eric S. Winer, Anthony G. Letai, Mark Alan Murakami, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 1509.

https://doi.org/10.1182/blood-2023-174216

Published: 2023

Journal Articles

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Jacqueline S. Garcia, Eric S. Winer, Ilene Galinsky, Julie Bergeron, Julie Asch, Matthew D. Seftel, Richard M Stone, Marlise R. Luskin, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 4238.

https://doi.org/10.1182/blood-2023-181014

Published: 2023

Journal Articles

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Blood (2023) 141 (15): 1884–1888.

https://doi.org/10.1182/blood.2022017686

Published: 2023

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN

Andrew A. Lane, Anthony S. Stein, Jacqueline S. Garcia, Jada L. Garzon, Ilene Galinsky, Marlise R. Luskin, Richard M. Stone, Eric S. Winer, Rebecca Leonard, Tariq I. Mughal, Christopher L Brooks, Marina Konopleva, Kristen E. Stevenson, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2021-147486

Published: 2021

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults

Marlise R. Luskin, Kristen E. Stevenson, Lourdes M. Mendez, Eunice S. Wang, Martha Wadleigh, Jacqueline S. Garcia, Richard M. Stone, Hyun Hwan An, Ella Hagopian, Ilene Galinsky, Lindsey Rae, Rebecca Leonard, Daniel J. DeAngelo, Mark A. Murakami

Blood (2021) 138 (Supplement 1): 2305.

https://doi.org/10.1182/blood-2021-149225

Published: 2021

Journal Articles

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-136235

Published: 2020

Journal Articles

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2 -Mutant Myeloproliferative Neoplasms

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141643

Published: 2020

Journal Articles

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Blood (2019) 134 (Supplement_1): 258.

https://doi.org/10.1182/blood-2019-126172

Published: 2019

Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS

Blood (2019) 134 (Supplement_1): 3908.

https://doi.org/10.1182/blood-2019-124966

Published: 2019

Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 2549.

https://doi.org/10.1182/blood-2019-126224

Published: 2019

Journal Articles

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Matthew Frigault, MD MSc, Megan Cartwright, PhD, Krista Marcello, BA, Timothy A Quill, PhD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Shilpa Paul, PharmD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 2199.

https://doi.org/10.1182/blood-2019-131533

Published: 2019

Journal Articles

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Blood (2019) 134 (Supplement_1): 2015.

https://doi.org/10.1182/blood-2019-126238

Published: 2019

Journal Articles

Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity

Peter Van Galen, PhD, Volker Hovestadt, PhD, Marc Wadsworth II, Travis Hughes, Gabriel Kenneth Griffin, MD, Julia A. Verga, Jason Stephansky, Timothy J. Pastika, Jennifer Lombardi Story, Geraldine S. Pinkus, MD, Olga Pozdnyakova, MD PhD, Ilene Galinsky, Richard M. Stone, MD, Timothy A. Graubert, MD, Alex K. Shalek, PhD, Jon C. Aster, MD PhD, Andrew A. Lane, MD PhD, Bradley E. Bernstein, MD PhD

Blood (2018) 132 (Supplement 1): 542.

https://doi.org/10.1182/blood-2018-99-113502

Published: 2018

Journal Articles

Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2659.

https://doi.org/10.1182/blood.V130.Suppl_1.2659.2659

Published: 2017

Journal Articles

Exploiting an Asp-Glu "Switch" in Glycogen Synthase Kinase 3 to Design Paralog Selective Inhibitors for Acute Myeloid Leukemia Treatment

Blood (2017) 130 (Supplement 1): 2075.

https://doi.org/10.1182/blood.V130.Suppl_1.2075.2075

Published: 2017

Journal Articles

Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia

Lina Benajiba, Nina Fenouille, Edyta Malolepsza, Jana M Ellegast, MD, Gabriela Alexe, Yana Pikman, MD, Frédéric Luciano, Ilene Galinsky, Daniel J. DeAngelo, MD, Richard M. Stone, MD, Patrick Auberger, PhD, Josee Guirouilh-Barbat, Bernard Lopez, Mehdi Khaled, Kasper Lage, Olivier Hermine, MD PhD, Michael Hemann, Alexandre Puissant, Kimberly Stegmaier, MD

Blood (2017) 130 (Supplement 1): 880.

https://doi.org/10.1182/blood.V130.Suppl_1.880.880

Published: 2017

NARROW

Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2 -Mutant Myeloproliferative Neoplasms

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity

Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid Leukemia

Exploiting an Asp-Glu "Switch" in Glycogen Synthase Kinase 3 to Design Paralog Selective Inhibitors for Acute Myeloid Leukemia Treatment

Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only